APOBEC3 deletion increases the risk of breast cancer: a meta-analysis
PDF | HTML | How to cite
Metrics: PDF 1615 views | HTML 1864 views | ?
Yali Han1,*, Qichao Qi2,*, Qin He3,*, Meili Sun1, Shuyun Wang1, Guanzhou Zhou4, Yuping Sun1
1Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, 250013, China
2Department of Neurosurgery, Qilu Hospital of Shandong University and Brain Science Research Institute, Shandong University, Jinan, 250012, China
3Department of Endocrine and Metabolism, Qilu Hospital of Shandong University, Jinan, 250012, China
4Department of General Surgery, Qilu Hospital of Shandong University, Jinan, 250012, China
*These authors have contributed equally to this work
Yuping Sun, email: [email protected]
Keywords: APOBEC3, copy number variation, breast cancer, cancer susceptibility
Received: May 14, 2016 Accepted: August 11, 2016 Published: September 1, 2016
Recently, a deletion in the human apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3) gene cluster has been associated with a modest increased risk of breast cancer, but studies yielded inconsistent results. Therefore we performed a meta-analysis to derive a more precise conclusion. Six studies including 18241 subjects were identified by searching PubMed and Embase databases from inception to April 2016. Pooled odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were evaluated under allele contrast, dominant, recessive, homozygous, and heterozygous models. All the analyses suggested a correlation of APOBEC3 deletion with increased breast cancer risk (D vs I: OR = 1.29, 95% CI = 1.23-1.36; D/D+I/D vs I/I: OR = 1.34, 95% CI = 1.26-1.43; D/D vs I/D+ I/I: OR = 1.51, 95% CI = 1.36-1.68; D/D vs I/I: OR = 1.75, 95% CI= 1.56-1.95; I/D vs I/I: OR = 1.28, 95% CI = 1.19-1.36). Stratified analysis by ethnicity showed that the relationship is stronger and more stable in Asians. In summary, our current work indicated that APOBEC3 copy number variations might have a good screening accuracy for breast cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.